Related Experiment Video

Updated: Sep 12, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.4K

Effect of Cardiac Rehabilitation on Cardiovascular Events in Patients With Advanced Chronic Kidney Disease

Tomoaki Hama1, Takatoshi Kakuta2, Kazushige Amano1

  • 1The Division of Cardiology, Department of Medicine, Tokai University Hachioji Hospital, Hachioji, Tokyo, Japan.

Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
|August 4, 2025
PubMed

Insights

Cardiac rehabilitation (CR) may significantly lower major adverse cardiovascular events (MACEs) in patients with advanced chronic kidney disease (CKD). This study found lower MACE rates in CKD patients who participated in CR compared to those who did not.

Area of Science:

  • Nephrology
  • Cardiology
  • Rehabilitation Medicine

Background:

  • Limited understanding of cardiac rehabilitation's impact on cardiovascular events in advanced chronic kidney disease (CKD).
  • Advanced CKD patients face high cardiovascular event risks.

Purpose of the Study:

  • To investigate the effect of cardiac rehabilitation (CR) on major adverse cardiovascular events (MACEs) in patients with advanced chronic kidney disease (CKD).

Main Methods:

  • Retrospective cohort study of 189 patients with estimated glomerular filtration rate < 30 mL/min/1.73 m².
  • Comparison of MACE incidence between patients who participated in CR versus those who did not.

Main Results:

  • 143 patients participated in CR, and 46 did not.
  • Lower cumulative MACE rates observed in the CR participation group (48%) compared to the non-participation group (61%, p=0.015).
  • Adjusted hazard ratio for cardiovascular events was 0.56 (95% CI, 0.35-0.89, p=0.014) for the CR participation group.

Conclusions:

  • Cardiac rehabilitation (CR) shows potential in reducing major adverse cardiovascular events (MACEs) for patients with advanced chronic kidney disease (CKD).
  • Further research is warranted to confirm these findings and optimize CR protocols for this population.
Abstract

Keywords:
advanced chronic kidney diseasecardiac rehabilitationmajor adverse cardiovascular event

More Related Videos

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.7K
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

20.9K

Related Concept Videos

Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
57
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
80
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
486
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
509
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
94